Angiogenesis is a multi-stage process that drives the generation of new blood and lymphatic vessels from pre-existing ones. It is highly active during embryogenesis, largely inactive during adulthood but reactivated during wound healing and under a number of pathological conditions including cancer and ocular diseases. In addition to endothelial cells, which line the walls of the vessels, several other cell types (pericytes, macrophages, progenitor cells...) also contribute to angiogenesis. A number of signaling pathways are activated and very finely tune the delicate morphogenetic events that…mehr
Angiogenesis is a multi-stage process that drives the generation of new blood and lymphatic vessels from pre-existing ones. It is highly active during embryogenesis, largely inactive during adulthood but reactivated during wound healing and under a number of pathological conditions including cancer and ocular diseases. In addition to endothelial cells, which line the walls of the vessels, several other cell types (pericytes, macrophages, progenitor cells...) also contribute to angiogenesis. A number of signaling pathways are activated and very finely tune the delicate morphogenetic events that ultimately lead to the formation of stable blood proof neovessels.
This book reviews recent advances in our understanding of the molecular and cellular mechanisms of angiogenesis, with a focus on how to integrate these observations into the context of developmental, post-natal and pathological neovascularization.
The book was published under the auspices of the French Angiogenesis Society. Most contributors are prominent members of this Society or international researchers who have actively contributed to the Annual Meetings of the Society.
Dr Jean-Jacques Feige, PhD, is President of the French Society of Angiogenesis, research director at INSERM (National Institute for Health and Medical Research) and runs an academic research laboratory (Biology of Cancer and Infection) in Grenoble, France. Dr Gilles Pagès , PhD, is deputy President of the French Society of Angiogenesis, research director at INSERM and runs an academic research group at the Institute for Research on Cancer and Aging of Nice (IRCAN) in the Centre Antoine Lacassagne of Nice. Dr Fabrice Soncin, PhD, is the former President of the French Society of Angiogenesis, research director at INSERM and runs an academic research team at the CNRS Institute of Biology of Lille, France.
Inhaltsangabe
Emergence of Endothelial Cells During Vascular Development.- Lymphatic Vascular Morphogenesis.- Finding New Partnerships; The Function of Individual Extracellular Receptor Domains in Angiogenic Signalling by VEGF Receptors.- Wnt/ Frizzled Signaling in the Vasculature.- BMP9, BMP10 And ALK1: An Emerging Vascular Signaling Pathway With Therapeutic Applications.- Apeling Signaling in Retinal Angiogenesis.- Emerging Role of the Two Related Basic Helix-Loop-Helix Proteins.- TAL1 and LYL1 In Angiogenesis.- Hypoxia and Extracellular Matrix Remodeling.- Sphingosine-1-Phosphate in Hypoxic Signaling.- Reciprocal Crosstalk Between Angiogenesis and Metabolism.- Endothelial Progenitor Cells and Cardiovascular Ischemic Diseases: Characterization, Functions and Potential Clinical Applications as Biomarker and Therapeutic Tools .- Endothelial Cell Reactions to Oxygen: Implications For Cancer.- Tumor Angiogenesis and Lymphangiogenesis: Microenvironmental Soil For Tumor Progression And Metastatic Dissemination.- Angiogenesis And Invasion in Malignant Glioma: Friends or Foes?.- Role of Endothelial Cells in Tumor Escape From Immunity.- Tumor High-Endothelial Venules and Lymphocyte Trafficking.- Post-Transcriptional Regulation of Angiogenesis Through AU-Rich Mrna Degradation: Potential Application in Cancer Therapy.- Antiangiogenic Drugs in Cancer Therapy, Effect on Advanced Renal Cell Carcinoma.- Anti-Angiogenic Therapies in Colorectal Cancer.- Resistance to Anti-Angiogenic Treatments via Up-Regulation of Substitution Pathways.- VEGF-A Splice Variants: Do They Play a Role in Tumor Responses to Anti-Angiogenic Therapies?.- Progenitor Endothelial Cells as Biomarkers of Anti-Vascular Agents.- Soluble Vascular Endothelial (VE)-Cadherin : Toward a Marker of Endotelial Dysfunction.- The Prognostic and Predictive Value of VEGF Across Various Tumor Types.
Emergence of Endothelial Cells During Vascular Development.- Lymphatic Vascular Morphogenesis.- Finding New Partnerships; The Function of Individual Extracellular Receptor Domains in Angiogenic Signalling by VEGF Receptors.- Wnt/ Frizzled Signaling in the Vasculature.- BMP9, BMP10 And ALK1: An Emerging Vascular Signaling Pathway With Therapeutic Applications.- Apeling Signaling in Retinal Angiogenesis.- Emerging Role of the Two Related Basic Helix-Loop-Helix Proteins.- TAL1 and LYL1 In Angiogenesis.- Hypoxia and Extracellular Matrix Remodeling.- Sphingosine-1-Phosphate in Hypoxic Signaling.- Reciprocal Crosstalk Between Angiogenesis and Metabolism.- Endothelial Progenitor Cells and Cardiovascular Ischemic Diseases: Characterization, Functions and Potential Clinical Applications as Biomarker and Therapeutic Tools .- Endothelial Cell Reactions to Oxygen: Implications For Cancer.- Tumor Angiogenesis and Lymphangiogenesis: Microenvironmental Soil For Tumor Progression And Metastatic Dissemination.- Angiogenesis And Invasion in Malignant Glioma: Friends or Foes?.- Role of Endothelial Cells in Tumor Escape From Immunity.- Tumor High-Endothelial Venules and Lymphocyte Trafficking.- Post-Transcriptional Regulation of Angiogenesis Through AU-Rich Mrna Degradation: Potential Application in Cancer Therapy.- Antiangiogenic Drugs in Cancer Therapy, Effect on Advanced Renal Cell Carcinoma.- Anti-Angiogenic Therapies in Colorectal Cancer.- Resistance to Anti-Angiogenic Treatments via Up-Regulation of Substitution Pathways.- VEGF-A Splice Variants: Do They Play a Role in Tumor Responses to Anti-Angiogenic Therapies?.- Progenitor Endothelial Cells as Biomarkers of Anti-Vascular Agents.- Soluble Vascular Endothelial (VE)-Cadherin : Toward a Marker of Endotelial Dysfunction.- The Prognostic and Predictive Value of VEGF Across Various Tumor Types.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497